Display options
Cite
Raiko K, Lyytikäinen A, Ekman M, et al. Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma. Clin Chim Acta. 2021;523:380-385doi: 10.1016/j.cca.2021.10.023.
Raiko, K., Lyytikäinen, A., Ekman, M., Nokelainen, A., Lahtinen, S., & Soukka, T. (2021). Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma. Clinica chimica acta; international journal of clinical chemistry, 523380-385. https://doi.org/10.1016/j.cca.2021.10.023
Raiko, Kirsti, et al. "Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma." Clinica chimica acta; international journal of clinical chemistry vol. 523 (2021): 380-385. doi: https://doi.org/10.1016/j.cca.2021.10.023
Raiko K, Lyytikäinen A, Ekman M, Nokelainen A, Lahtinen S, Soukka T. Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma. Clin Chim Acta. 2021 Dec;523:380-385. doi: 10.1016/j.cca.2021.10.023. Epub 2021 Oct 21. PMID: 34688634.
Copy Download .nbib Format: NLM
Share it on

Clin Chim Acta. 2021 Dec;523:380-385. doi: 10.1016/j.cca.2021.10.023. Epub 2021 Oct 21.

Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma.

Clinica chimica acta; international journal of clinical chemistry

Kirsti Raiko, Annika Lyytikäinen, Miikka Ekman, Aleksi Nokelainen, Satu Lahtinen, Tero Soukka

Affiliations

  1. Department of Biotechnology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland. Electronic address: [email protected].
  2. Department of Biotechnology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland.

PMID: 34688634 DOI: 10.1016/j.cca.2021.10.023

Abstract

BACKGROUND AND AIMS: Upconverting nanoparticles (UCNPs) are attractive reporters for immunoassays due to their excellent detectability. Assays sensitive enough to measure baseline level of cardiac troponin I cTnI in healthy population could be used to identify patients at risk for cardiovascular disease. Aiming for a cTnI assay of such sensitivity, the surface chemistry of the nanoparticles as well as the assay reagents and the protocol were optimized for monodispersity of the UCNP antibody conjugates (Mab UCNPs) and to minimize their non-specific interactions with the solid support.

MATERIALS AND METHODS: UCNPs were coated with poly(acrylic acid) via two-step ligand exchange and conjugated with monoclonal antibodies. The conjugates were applied in a microplate-based sandwich immunoassay using a combination of two capture antibodies to detect cTnI. Assay was evaluated according to guidelines of Clinical & Laboratory Standards Institute.

RESULTS: The limit of detection and limit of blank of the assay were 0.13 ng/L and 0.01 ng/L cTnI, respectively. The recoveries were >90% in spiked plasma in the linear range. The within- and between-run imprecisions were <10%.

CONCLUSION: The results demonstrate that UCNPs enable quantification of cTnI concentrations expected in plasma of healthy individuals and could be used to identify patients at risk for cardiovascular disease.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Keywords: Aggregation; Analytical methods; Luminescence; Nanoparticles; Surface chemistry

Publication Types